Innovative, targeted nanoparticles for PET/CT imaging and photothermal ablation (PTA) therapy were designed based on the attachment of cyclic KRGDF peptide to the surface of chelator-free [
INTRODUCTION
Positron emission tomography (PET) is one of the most rapidly growing areas of medical imaging, because of its ability to visualize, characterize, and measure biological processes at the cellular, subcellular, and molecular levels in living subjects using noninvasive procedures 1 . In previous studies, a process for the rapid synthesis of radioactive [ 64 Cu ]CuS nanoparticles were successfully developed. Further investigation showed that PEG-[ 64 Cu ]CuS nanoparticles can act as an efficient radiotracer for PET imaging, and PEG-CuS nanoparticles can be used for PTA therapy of cancer cells using nearinfrared (NIR) laser irradiation 2 . Angiogenesis is required for both tumor growth and metastasis because tumors cannot grow beyond 1-2 mm in size without the formation of neovasculature required to provide oxygen and nutrients 3 . This process is dependent on vascular endothelial cell migration and invasion, which is initially mediated by alterations in the expression of cell-surface molecules known as integrins 4 . The ανβ3 integrin is an endothelial cell receptor for extracellular matrix (ECM) proteins harboring the RGD sequence. The receptors are expressed at low levels on epithelial and mature endothelial cells in normal tissues but are highly unregulated and expressed on activated endothelial cells present in the neovasculature of tumors, such as breast cancer, gliobastomsas and ovarian cancer 5 . We propose the development of targeted nanoparticles with CuS nanoparticles attached to cyclic KRGDF peptide through a PEG linker. To achieve this purpose, we use alkynemodified cyclic KRGDF peptides to couple with the azide-functionalized PEG via Huisgen's 1, 3 dipolar cycloaddition, which is catalyzed by copper sulfate and sodium ascorbate in aqueous solution. This RGDnanoparticle system may be suitable for targeted PET/CT imaging and PTA therapy of cancer cells using NIR laser irradiation.
EXPERIMENTAL METHODS
In order for "click" chemistry to be applied to the development of peptide-targeted nanoparticles, we modified the cyclic KRGDF with alkyne moiety and thiol-PEG-amine with azide moiety. Deprotection and cleavage of the conjugates from the solid support were carried out simultaneously by treatment with TFA/H 2 O/TES (95/1/4, v/v/v) to yield alkyne-cyclic KRGDF. The difunctional 5 kDa thiol-PEG-azide was prepared with thiol-PEG-amine linked to synthesized succinimidyl 4-azidobutyrate. The peptide was confirmed and purified by LC/MS analysis and the thiol-PEG-azide was characterized with 1 H NMR. The targeted peptide will be added to the surface of CuS-PEG nanoparticle. To confirm the occurrence of targeted CuS nanoparticles, IR, TEM and LC/MS will be used for characterization. The particle size and the morphology of nanoparticles will be characterized using TEM and dynamic light scattering (DLS). UV−vis spectra of targeted CuS nanoparticles will be recorded.
RESULTS AND DISCUSSION
The structure of the synthesized succinimidyl 4-azidobutyrate was determined with 1 H NMR (Figure 1 ). And the NMR spectra (Figure 2 ) of HS-PEG 5000 -N 3 showed that the modification of azide was successful. The confirmation of the alkyne-cyclic RGDfK was determined by using LC/MS (Figure 3 ). To confirm the modification with PEG, the CuS-PEG-N 3 nanoparticles were characterized by using 1 H NMR with the dry sample dispersed in D 2 O. In the spectra (Figure 4) , a peak at 3.65 ppm, characteristic of PEG, suggested that the CuS nanoparticles were coated by HS-PEG-N 3 . The hydrodynamic sizes and zeta potential of CuS and CuS-PEG-N 3 nanoparticles were determined with DLS. The particle size and zeta potential for CuS-PEG-N 3 were increased from 12 nm to 21 nm and -50.63 mV to -22.6 mV, respectively, due to the PEG coating (Table 1 and Figure 5 ). The TEM image (Figure 6 ) of the CuS-PEG nanoparticles showed that the nanoparticles were well dispersed and relatively uniform in size (~ 20 nm). 100 nm Figure 6 . TEM of CuS-PEG Nanoparticles
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The optical spectra of CuS and Cu-PEG-N3 were investigated by using UV-vis spectra (Figure 7) . Both of the nanoparticles exhibited similar absorption in the NIR region confirming that the PEG coating on the CuS nanoparticles did not change the optical property of CuS as a PTA therapy agent. 
CONCLUSION
In this present work, we successfully synthesized the CuS-PEG-N 3 nanoparticles and cyclic (RGDfK) peptide which will be used to modify the CuS-PEG-N 3 nanoparticles. The confirmation of the final product will be analyzed with TEM, UV-vis spectra and LC/MS. In the future, the in vitro and in vivo efficacy of these final targeted nanoparticles and their radioactivity will be determined in several cell lines and animal models.
